Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines

Acta Pharmacologica Sinica

Volumn 30, Issue 11, 2009, Pages 1529-1536

  Meng, Hai Tao ^a   Li, Lu ^a   Liu, Hui ^a   Wang, Ying ^a   Li, Gong Chu ^b   Qian, Wen Bin ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Apoptosis; HL 60 cells; Homoharringtonine; Kasumi 1 cells; KG 1 cells; Oncolytic adenovirus; Synergy; TRAIL

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CASPASE 8; CASPASE 9; CONDITIONALLY REPLICATING ADENOVIRUS; CRYSTAL VIOLET; E1A PROTEIN; FLUORESCEIN ISOTHIOCYANATE; HOMOHARRINGTONINE; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN BID; PROTEIN MCL 1; SG235 TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; PROTEIN CONTENT; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; HARRINGTONINES; HUMANS; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 70449331499     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.147     Document Type: Article

References (38)

1. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787
2. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002; 3: 17-26.
3. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003; 2003: 110-137
4. Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411-427
5. Liu TC, Kim D. Viruses with deletions in antiapoptotic genes as potential oncolytic agents. Oncogene 2005; 24: 6069-6079
6. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376
7. Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 2008; 22: 361-369
8. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
9. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139
10. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412
11. Tuve S, Wang H, Ware C, Liu Y, Gaqqar A, Bernt K, et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006; 80: 12109-12120
12. Reddy PS, Ganesh S, Yu DC. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin Cancer Res 2006; 12: 2869-2878
13. Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, et al. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther 2009; 5: 1387-1397
14. Wang G, Li G, Liu H, Yang C, Yang X, Jin J, et al. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med 2009; 11: 477-485
15. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485-495
16. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933-946
17. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A, et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 2007; 148: 5186-5194
18. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: history, current research, and future direction.Cancer 2001; 92: 1591-1605
19. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1185-1188
20. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996; 10: 40-42
21. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322-3326
22. Warrell RP Jr, Coonley CJ, Gee TS. Homoharringtonine: An effective new drug for remission induction in refractory non-lymphoblastic leukemia. J Clin Oncol 1985; 3: 617-621
23. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008; 100: 580-595
24. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524
25. Chu RL, Post DF, Khuri FR, Van Meir EG. Use of replicating oncolytic adenovirus in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312
26. Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on longterm prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 799-804.
27. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005; 12: 141-161
28. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009; 16: 473-488
29. Kantarjian H, Keating M, McCredie K, Koller CA, McCredie KB, Freireich EJ. Phase II study of homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989; 63: 813-817
30. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006; 20: 1361-1367
31. Luo CY, Tang JY, Wang YP. Homoharringtonine: a new treatment option for myeloid leukemia. Hematology 2004; 9: 259-270
32. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis acute myeloid leukemia. Ann Onc 1998; 9: 159-165
33. Addeo R, Caraglia M, Baldi A, D'Angelo V, Casale F, Crisci S, et al. Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL). Cancer Biol Ther 2005; 4: 32-38
34. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87: 1140-1146 (Pubitemid 26043542)
35. Guo BC, Xu YH. Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells. Cell Res 2001; 11: 101-106
36. Lamothe B, Aggarwal BB. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J Interferon Cytokine Res 2002; 22: 269-279
37. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162
38. Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosisinducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 2001; 7: 3874-3883